


Oncology
2023-04-21

MDA-MB-231 and NUGC4 PBMC-NCG xenograft models were included in this study. In the case of MDA-231, 3 donors were enrolled in this study at the same time. The TGITV of 3 donors were 17.66-MB%, 27.14%, and 52.40%, especially. In the case of NUGC4, 2 donors were enrolled in this study at the same time. The TGITV of 2 donors were 4.75% and 20.74%, especially. The results of two experiments suggested that the anti-PDL1 treatment are donor dependent, which is similar to the clinical trials.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
